A pharmacoeconomic evaluation of 7-valent pneumococcal conjugate vaccine in Canada

Clinical Infectious Diseases

Volumn 36, Issue 3, 2003, Pages 259-268

  Lebel, Marc H ^e   Kellner, James D ^e   Ford Jones, E Lee ^a   Hvidsten, Kyle ^c   Wang, Edward C Y ^b   Ciuryla, Vincent ^d   Arikian, Steve ^c   Casciano, Roman ^c  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b Wyeth Pharmaceuticals   (Canada)

^c Analytica Group   (United States)

^d PFIZER INC   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE;

ALGORITHM; ARTICLE; BACTEREMIA; CANADA; CHILD; COST EFFECTIVENESS ANALYSIS; DEATH; DRUG COST; DRUG EFFICACY; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MENINGITIS; OTITIS MEDIA; PNEUMONIA; PRIORITY JOURNAL;

CANADA; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HUMANS; INFANT; INFANT, NEWBORN; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT (HEALTH CARE); PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; RISK ASSESSMENT; VACCINES, CONJUGATE;

EID: 0037311409     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/345833     Document Type: Article

References (25)

1. Scheifele D. The burden of pneumococcal infections in children. Paediatric Child Health 2001; 6(Suppl B):5B-8B.
2. Henrichsen J. Six newly recognized types of Streptococcus pneumoniae. J Clin Microbiol 1995; 33:2759-62
3. Scheifele D, Halperin S, Pelletier L, et al. Invasive pneumococcal infections in Canadian Children 1991-1998: implications for new vaccination strategies. Clin Infect Dis 2000; 31:58-64.
4. National Advisory Committee on Immunization Practices. Statement on recommended use of pneumococcal conjugate vaccine. Can Commun Dis Rep 2002; 28:1-24.
5. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993; 13:322-38.
6. Bjornson G, Scheifele D, Binder F, et al. Population-based incidence rate of invasive pneumococcal infection in children: Vancouver, 1994-1998. Can Commun Dis Rep 2000; 26:149-51.
7. Bjornson G, Scheifele D, Halperin S. Population-based incidence rates of invasive pneumococcal infection in children in 7 centers across Canada. Members of the CPS/LCDC Immunization Monitoring Program, Active (IMPACT). In: Program and abstracts of the 4th Annual Conference on Vaccine Research (Washington, DC). Bethesda, MD: National Foundation for Infectious Diseases, 2001. Available at: http://www.nfid.org/conferences/vaccine01/abstracts/.
8. Jadavji T, Law B, Lebel MH, et al. A practical guide for diagnosis and treatment of pediatric pneumonia. CMAJ 1997; 156:S703-11.
9. Wang EL, Einarson TR, Kellner JD, Conly JM. Antibiotic prescribing for Canadian preschool children: evidence of overprescribing for viral respiratory infections. Clin Infect Dis 1999;29:155-60.
10. Pukander J, Luotonen J, Sipila M, Timonen M, Karma P. Incidence of acute otitis media. Acta Otolaryngol 1982; 93:447-53.
11. Desai SN, Kellner JD, Drummond D. Population-based, age-specific myringotomy with tympanostomy tube insertion rates in Calgary, Canada. Pediatr Infect Dis J 2002;21:348-50.
12. Black S, Shinefield H, Fireman B, et al. Efficacy, safety, and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000; 19:187-95.
13. Black S, Shinefield H, Ray P, et al. Efficacy of heptavalent conjugate pneumococcal vaccine (Wyeth Lederle) in 37,000 infants and children: impact on pneumonia, otitis media and update on invasive disease - results of the Northern California Kaiser Permanente Efficacy Trial [abstract 1398]. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1999.
14. Eskola J, Anttila M. Pneumococcal conjugate vaccines. Pediatr Infect Dis J 1999; 18:543-51.
15. Barbour ML, Booy R, Crook DWM, et al. Haemophilus influenzae type b carriage and immunity four years after receiving the Haemophilus influenzae oligosaccharide-CRM197 (HbOC) conjugate vaccine. Pediatr Infect Dis J 1993; 12:478-84.
16. Capra A. The cost of otitis media. Pediatr Infect Dis J 2000; 19:354-5.
17. Statistics Canada. Earnings of men and women [publication no.13-217-XPB]. Ottawa: Statistics Canada, 1997.
18. The world factbook. Washington, DC: Office of Public Affairs, Central Intelligence Agency, 2002. Available at: http://www.cia.gov/cia/publications/factbook/.
19. Dagan R, Melamed R, Muallem M, et al. Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine. J Infect Dis 1996; 174:1271-8.
20. Dagan R, Givon-Lavi N, Porat N, Sikuler-Cohen M, Fraser D. Immunization of toddlers attending day care centers with a 9-valent conjugate pneumococcal vaccine reduces transmission of Streptococcus pneumoniae and antibiotic resistant S. pneumoniae to their young siblings. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 2000.
21. Black SB, Shinefield HR, Hansen J, Elvin L, Laufer D, Malinoski F. Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2001; 20:1105-7.
22. Scheifele D, Halperin S, Pelletier L, et al. Reduced susceptibility to penicillin among pneumococci causing invasive infection in children in Canada, 1991 to 1998. Can J Infect Dis 2001; 12:241-6.
23. Low DE, de Azavedo J, Weiss K, et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in Canada during 2000. Antimicrob Agents Chemother 2002; 46:1295-301.
24. Lieu TA, Ray GT, Black SB, et al. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. JAMA 2000; 283:1460-8.
25. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992; 146:473-81.